OATP-E Inhibitors

Chemical inhibitors of OATP-E include a range of compounds that interact with the protein to impede its transport function. Cyclosporin A, for instance, binds to cyclophilins, which are implicated in the proper folding and trafficking of OATP-E, leading to its functional inhibition. This inhibition occurs because the cyclophilins, when bound to Cyclosporin A, are unable to assist in the folding or trafficking process, resulting in a misfolded or improperly localized transporter. Rifampicin acts directly on OATP-E, blocking substrate binding and thereby inhibiting its activity. This direct interaction ensures that the substrates cannot access the transporter's binding site, effectively shutting down the transport mechanism that OATP-E facilitates. Similarly, Bromosulfophthalein competes with endogenous substrates for binding sites on OATP-E, leading to a blockade of transport activity, and Chrysin interferes with the ATP-dependent uptake of substrates, suggesting its affinity for binding sites that overlap with those of OATP-E substrates.

Further inhibiting OATP-E, Naringin engages with the transporter through steric hindrance, which obstructs the pathway necessary for physiological substrates to enter or exit through the transporter. Erythromycin also exhibits inhibitory action on OATP-E by preventing the translocation of substrates across the cell membrane through direct interaction with the transporter. Troglitazone and Indomethacin both inhibit the protein by binding to its substrate site, with Troglitazone preventing the influx of substrates and Indomethacin blocking other substrates' uptake through competitive binding. Sulfinpyrazone and Sulfasalazine share a similar mechanism, where they compete with endogenous substrates of OATP-E, reducing its transport function either by binding-induced conformational change or direct competition. Nicotinic acid is believed to inhibit OATP-E by occupying the binding site on the transporter, thereby blocking its functionality. Lastly, Fexofenadine acts as a competitive inhibitor, binding to OATP-E and preventing the transport of other substrates without being transported itself. Each of these chemicals exhibits a specific interaction with OATP-E that results in the inhibition of its transport capabilities, whether through competitive binding, direct interaction, or interference with necessary conformational or trafficking processes.